Cliniphar Ltd. (TYO:432A)

Cliniphar Income Statement

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024
Period Ending	Mar 31, 2025	Mar 31, 2024
Revenue	3,585	3,526
Revenue Growth (YoY)	1.67%	-
Cost of Revenue	2,920	2,852
Gross Profit	665	674
Selling, General & Admin	517	506
Operating Expenses	526	513
Operating Income	139	161
Interest Expense	-6	-6
Interest & Investment Income	14	2
Currency Exchange Gain (Loss)	1	2
Other Non Operating Income (Expenses)	25	5
EBT Excluding Unusual Items	173	164
Gain (Loss) on Sale of Investments	6	-548
Gain (Loss) on Sale of Assets	19	-
Asset Writedown	-	-3
Other Unusual Items	-	-162
Pretax Income	198	-549
Income Tax Expense	8	64
Net Income	190	-613
Net Income to Common	190	-613
Shares Outstanding (Basic)	1	1
Shares Outstanding (Diluted)	1	1
EPS (Basic)	190.00	-613.00
EPS (Diluted)	190.00	-613.00
Gross Margin	18.55%	19.11%
Operating Margin	3.88%	4.57%
Profit Margin	5.30%	-17.39%
EBIT	139	161
EBIT Margin	3.88%	4.57%
Effective Tax Rate	4.04%	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.